Developer docs
API playgroundTry for free, no card

Search company profiles

MabGenesis

Full company profile

uuid00036oy

Namestring
MabGenesis
Legal namestring
MabGenesis(マブジェネシス)株式会社
Websiteurl
mabgenesis.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

MabGenesis (マブジェネシス株式会社) is a Yokohama, Japan-based private biotech startup founded to commercialize more than 30 years of domestic academic antibody research. The company operates as a B2B therapeutic antibody discovery platform serving pharmaceutical partners in both human and animal health. Its technology stack centers on the proprietary MOURA Library — a phage display antibody library with 10^11 clones derived from bone marrow and spleen immune cells — offered across specialized variants for human (hMOURA), canine (cMOURA, 10^10), feline (fMOURA, 10^10), camelid VHH (cVHH MOURA, 10^11), and a cancer cell-specific subset library built from screening ~50 cancer cell lines. The IMPACT screening method complements these libraries by enabling efficient isolation of phage antibodies against cell membrane antigens, including those recognizing subtle conformational differences that conventional technologies cannot capture.

MabGenesis translates this platform into revenue through three channels: research collaborations (a structured 4-step antibody discovery service), a discovery pipeline offering for partners seeking novel antibody therapeutics, and technology licensing of the library and screening IP. Notable internal and out-licensed antibody assets include an anti-TfR1 antibody progressed into a Phase 1 trial by another company, an anti-Integrin A6B4 complex antibody (world's first), an anti-CADM1/IgSF4 human antibody (world's first), and an anti-EGF Receptor antibody showing superior tumor suppression versus cetuximab in mouse models. Granted IP includes US 9598496 B2, WO 2015034052 A1, and 特開2015-7030, supported by founder/CTO Kurosawa Gene's peer-reviewed methodology publications.

Business operations are concentrated in two segments: human pharmaceuticals (focused on oncology and zoonotic disease with high unmet needs, addressing a ¥35 trillion 2023 global antibody drug market) and companion animal antibody therapeutics (targeting a projected ¥1 trillion global market by 2032). Named strategic partners span the global animal-health majors (Ceva, MSD Animal Health, Virbac) and Japanese partners (Kyoritsu Seiyaku, Nippon Soda). Across three disclosed funding rounds (2020, 2020, 2024) the company has raised approximately $5.57M total; headcount sits in the 11–50 range, consistent with a capital-efficient preclinical platform rather than a scaling clinical-stage commercial organization.

Short descriptiontext

MabGenesis is a Yokohama-based private biotech startup that commercializes 30+ years of Japanese academic antibody research, offering pharmaceutical partners proprietary phage display antibody libraries (MOURA) and an IMPACT screening method to discover first-in-class therapeutic monoclonal antibodies for human and companion animal applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersYokohama, Japan
HQ citystring
Yokohama
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
monoclonal antibody discovery, phage display library, therapeutic antibody development, animal health biologics, antibody screening technology
Industry4 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Therapeutic Antibody Discovery & Biopharmaceutical R&D Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Research Collaboration
TypeProfessional Services
Description

Collaborative research services where MabGenesis leverages its MOURA Library and IMPACT technology to rapidly and efficiently discover target antibodies for pharmaceutical partners.

mabgenesis.com
2Technology Licensing
TypeLicensing Royalties
Description

Licensing of proprietary antibody library and screening technologies to pharmaceutical companies for drug discovery research.

mabgenesis.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1MOURA Library
Description

Proprietary phage display antibody library with 10^11 clones for antibody discovery, available in human (hMOURA), cancer cell-specific, camelid VHH (cVHH), canine (cMOURA), and feline (fMOURA) variants.

mabgenesis.com
+1 more record
Core offering1 text field

MabGenesis commercializes a proprietary antibody discovery platform — the MOURA Library (human, canine, feline, camelid VHH, and cancer cell-specific phage display libraries) together with the IMPACT screening method — to deliver therapeutic monoclonal antibody candidates for human and companion animal applications. The company sells its discovery services and platforms through research collaboration agreements, pipeline co-development, and technology licensing to pharmaceutical and animal health partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Anti-tumor activity superior to Cetuximab in cancer mouse models
+3 more records
Product overview1 text field

MabGenesis is a startup biopharmaceutical company that commercializes over 30 years of academic antibody research. The company provides a technology platform consisting of the proprietary MOURA Library (phage display antibody libraries for humans, canines, and felines with up to 10^11 diversity) and the IMPACT screening technology for efficient monoclonal antibody isolation. The portfolio includes multiple drug candidates targeting cancer (anti-TfR1, anti-Integrin A6B4, anti-CADM1, anti-EGF Receptor antibodies). Services offered include collaborative research, discovery pipeline, and technology licensing for pharmaceutical partners seeking to develop first-in-class and best-in-class therapeutic monoclonal antibody drugs for both human and companion animal applications.

Product and service5 records
1MOURA Library Antibody Platform (Human hMOURA, Canine cMOURA, Feline fMOURA, Camelid VHH cVHH MOURA, and Cancer Cell-Specific Subset variants)
CategoryAntibody Discovery Platform / Licensable Technology
Description

A family of proprietary phage display antibody libraries providing the world's largest, functionally optimized antibody repertoires for human, canine, feline, and camelid VHH antibody discovery, plus a cancer cell-specific subset. Sold as a licensable platform for pharmaceutical and animal health partners.

2IMPACT Screening Method
CategoryAntibody Screening Technology / Licensable IP
Description

Efficient proprietary phage antibody screening technology that enables isolation of high-quality antibodies against cell membrane antigens, including difficult targets that recognize subtle structural differences. Sold together with the MOURA Library as a licensable technology package.

3Collaborative Research Service
CategoryResearch Collaboration / Custom Antibody Discovery
Description

A 4-step custom antibody discovery service for pharmaceutical partners covering panning/screening, scFv identification, IgG conversion/expression, and IgG functional evaluation, leveraging proprietary MOURA Library and IMPACT technology.

4Discovery Pipeline
CategoryTherapeutic Antibody Pipeline / Co-Development Offering
Description

Drug discovery pipeline offering for pharmaceutical partners seeking to develop novel therapeutic monoclonal antibody candidates, with assets including anti-TfR1, anti-Integrin A6B4, anti-CADM1/IgSF4, and anti-EGFR antibody candidates.

5Technology License
CategoryTechnology Licensing
Description

Licensing arrangement where MabGenesis grants partners rights to use its proprietary antibody library (MOURA) and IMPACT screening technologies for the partners' own internal drug discovery programs.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Ceva is listed as a business partner of MabGenesis. Ceva is a major animal health company that could potentially collaborate on animal antibody drug development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

MSD Animal Health is listed as a business partner. As one of the largest animal health companies globally, potential collaboration areas include companion animal antibody therapeutics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Virbac is listed as a business partner. As a global animal health company, potential collaboration on veterinary antibody products.

4共立製薬 (Kyoritsu Seiyaku)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Kyoritsu Seiyaku is listed as a business partner. Japanese animal health company that may collaborate on domestic or international antibody drug development.

mabgenesis.com
5日本曹達 (Nippon Soda)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Nippon Soda is listed as a business partner. Japanese chemical and pharmaceutical company with potential for collaboration in human or animal health antibody therapeutics.

mabgenesis.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Biologics CDMO offering antibody discovery, engineering, and manufacturing services. Comparable as a B2B antibody discovery service provider with broader manufacturing scope.

TypeDirect peer
Description

Vancouver-based antibody discovery platform company using single-cell screening and proprietary libraries to discover monoclonal antibody candidates for pharma partners. Directly comparable B2B business model centered on antibody out-licensing and platform partnerships.

TypeDirect peer
Description

Leading yeast-display-based antibody discovery platform providing partnered antibody discovery, optimization, and licensing to pharma. Closely mirrors MabGenesis's display library + pharma partnership model.

TypeDirect peer
Description

Antibody discovery and development company using proprietary somatic hypermutation platforms to generate therapeutic mAbs for immuno-oncology and inflammation. Comparable as a discovery-stage antibody platform monetizing via licensing and partnerships.

TypeEmerging player
Description

Synthetic DNA and antibody library provider with phage-display libraries sold to pharma and biotech. Comparable via display-library technology offerings, though broader in synthetic biology scope.

6Harbour BioMed
TypeEmerging player
Description

Biotech specializing in heavy-chain-only antibody (HCAb) and bispecific discovery using transgenic mouse and phage display platforms. Comparable via display-library technology and antibody platform licensing to pharma.

TypeEmerging player
Description

Developer of T cell engagers based on a humanized VHH (camelid single-domain antibody) platform. Comparable to MabGenesis's cVHH MOURA Library work on VHH-derived therapeutics.

TypeBroad incumbent
Description

Global biologics CRO/CDMO offering antibody discovery, development, and manufacturing services to pharma. Comparable as a large-scale antibody discovery service provider, though broader scope and scale than MabGenesis.

TypeBroad incumbent
Description

Largest global animal health company and a potential customer/partner for companion animal antibody therapeutics. Comparable as a major channel for veterinary biologics — relevant to MabGenesis's animal health partnerships.

TypeRegional player
Description

Animal diagnostics and veterinary products company with deep companion animal channel reach. Relevant as a potential downstream partner or comparator in the companion animal therapeutics/diagnostics ecosystem.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MabGenesis

Therapeutic Antibody Discovery & Biopharmaceutical R&D Servicesmabgenesis.com

MabGenesis is a Yokohama-based private biotech startup that commercializes 30+ years of Japanese academic antibody research, offering pharmaceutical partners proprietary phage display antibody libraries (MOURA) and an IMPACT screening method to discover first-in-class therapeutic monoclonal antibodies for human and companion animal applications.

What MabGenesis does

MabGenesis (マブジェネシス株式会社) is a Yokohama, Japan-based private biotech startup founded to commercialize more than 30 years of domestic academic antibody research. The company operates as a B2B therapeutic antibody discovery platform serving pharmaceutical partners in both human and animal health. Its technology stack centers on the proprietary MOURA Library — a phage display antibody library with 10^11 clones derived from bone marrow and spleen immune cells — offered across specialized variants for human (hMOURA), canine (cMOURA, 10^10), feline (fMOURA, 10^10), camelid VHH (cVHH MOURA, 10^11), and a cancer cell-specific subset library built from screening ~50 cancer cell lines. The IMPACT screening method complements these libraries by enabling efficient isolation of phage antibodies against cell membrane antigens, including those recognizing subtle conformational differences that conventional technologies cannot capture.

MabGenesis translates this platform into revenue through three channels: research collaborations (a structured 4-step antibody discovery service), a discovery pipeline offering for partners seeking novel antibody therapeutics, and technology licensing of the library and screening IP. Notable internal and out-licensed antibody assets include an anti-TfR1 antibody progressed into a Phase 1 trial by another company, an anti-Integrin A6B4 complex antibody (world's first), an anti-CADM1/IgSF4 human antibody (world's first), and an anti-EGF Receptor antibody showing superior tumor suppression versus cetuximab in mouse models. Granted IP includes US 9598496 B2, WO 2015034052 A1, and 特開2015-7030, supported by founder/CTO Kurosawa Gene's peer-reviewed methodology publications.

Business operations are concentrated in two segments: human pharmaceuticals (focused on oncology and zoonotic disease with high unmet needs, addressing a ¥35 trillion 2023 global antibody drug market) and companion animal antibody therapeutics (targeting a projected ¥1 trillion global market by 2032). Named strategic partners span the global animal-health majors (Ceva, MSD Animal Health, Virbac) and Japanese partners (Kyoritsu Seiyaku, Nippon Soda). Across three disclosed funding rounds (2020, 2020, 2024) the company has raised approximately $5.57M total; headcount sits in the 11–50 range, consistent with a capital-efficient preclinical platform rather than a scaling clinical-stage commercial organization.

MabGenesis firmographics

Firmographics
Name
MabGenesis
Legal name
MabGenesis(マブジェネシス)株式会社
Website
https://mabgenesis.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
MabGenesis is a Yokohama-based private biotech startup that commercializes 30+ years of Japanese academic antibody research, offering pharmaceutical partners proprietary phage display antibody libraries (MOURA) and an IMPACT screening method to discover first-in-class therapeutic monoclonal antibodies for human and companion animal applications.
Ownership category
akta.pro rank

MabGenesis industry classification

Industry
Product category
Therapeutic Antibody Discovery & Biopharmaceutical R&D Services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Monoclonal antibody discovery
  • Phage display library
  • Therapeutic antibody development
  • Animal health biologics
  • Antibody screening technology

Where MabGenesis is headquartered

Location

Headquarters

HQ city
Yokohama
HQ country
Japan
HQ region
Asia

Markets served

MabGenesis business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Research Collaboration: Collaborative research services where MabGenesis leverages its MOURA Library and IMPACT technology to rapidly and efficiently discover target antibodies for pharmaceutical partners.
  2. Technology Licensing: Licensing of proprietary antibody library and screening technologies to pharmaceutical companies for drug discovery research.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

MabGenesis product offering

Product offering

Core offering

MabGenesis commercializes a proprietary antibody discovery platform — the MOURA Library (human, canine, feline, camelid VHH, and cancer cell-specific phage display libraries) together with the IMPACT screening method — to deliver therapeutic monoclonal antibody candidates for human and companion animal applications. The company sells its discovery services and platforms through research collaboration agreements, pipeline co-development, and technology licensing to pharmaceutical and animal health partners.

Product overview

MabGenesis is a startup biopharmaceutical company that commercializes over 30 years of academic antibody research. The company provides a technology platform consisting of the proprietary MOURA Library (phage display antibody libraries for humans, canines, and felines with up to 10^11 diversity) and the IMPACT screening technology for efficient monoclonal antibody isolation. The portfolio includes multiple drug candidates targeting cancer (anti-TfR1, anti-Integrin A6B4, anti-CADM1, anti-EGF Receptor antibodies). Services offered include collaborative research, discovery pipeline, and technology licensing for pharmaceutical partners seeking to develop first-in-class and best-in-class therapeutic monoclonal antibody drugs for both human and companion animal applications.

Differentiator

Problem solved

Functional benefit

Brands

  • MOURA Library: Proprietary phage display antibody library with 10^11 clones for antibody discovery, available in human (hMOURA), cancer cell-specific, camelid VHH (cVHH), canine (cMOURA), and feline (fMOURA) variants.
  • IMPACT

Products and services

  • MOURA Library Antibody Platform (Human hMOURA, Canine cMOURA, Feline fMOURA, Camelid VHH cVHH MOURA, and Cancer Cell-Specific Subset variants) A family of proprietary phage display antibody libraries providing the world's largest, functionally optimized antibody repertoires for human, canine, feline, and camelid VHH antibody discovery, plus a cancer cell-specific subset. Sold as a licensable platform for pharmaceutical and animal health partners.
  • IMPACT Screening Method Efficient proprietary phage antibody screening technology that enables isolation of high-quality antibodies against cell membrane antigens, including difficult targets that recognize subtle structural differences. Sold together with the MOURA Library as a licensable technology package.
  • Collaborative Research Service A 4-step custom antibody discovery service for pharmaceutical partners covering panning/screening, scFv identification, IgG conversion/expression, and IgG functional evaluation, leveraging proprietary MOURA Library and IMPACT technology.
  • Discovery Pipeline Drug discovery pipeline offering for pharmaceutical partners seeking to develop novel therapeutic monoclonal antibody candidates, with assets including anti-TfR1, anti-Integrin A6B4, anti-CADM1/IgSF4, and anti-EGFR antibody candidates.
  • Technology License Licensing arrangement where MabGenesis grants partners rights to use its proprietary antibody library (MOURA) and IMPACT screening technologies for the partners' own internal drug discovery programs.

Quantifiable outcome

  • Anti-tumor activity superior to Cetuximab in cancer mouse models
  • +3 more outcomes

Companies that use MabGenesis

Customer profile

Segments2 records

Ideal customer profiles2 records

MabGenesis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

MabGenesis partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • CevacoreStrategic or Co-development PartnerCeva is listed as a business partner of MabGenesis. Ceva is a major animal health company that could potentially collaborate on animal antibody drug development.
  • MSD Animal Health (MSDアニマルヘルス)coreStrategic or Co-development PartnerMSD Animal Health is listed as a business partner. As one of the largest animal health companies globally, potential collaboration areas include companion animal antibody therapeutics.
  • VirbaccoreStrategic or Co-development PartnerVirbac is listed as a business partner. As a global animal health company, potential collaboration on veterinary antibody products.
  • 共立製薬 (Kyoritsu Seiyaku)coreStrategic or Co-development PartnerKyoritsu Seiyaku is listed as a business partner. Japanese animal health company that may collaborate on domestic or international antibody drug development.
  • 日本曹達 (Nippon Soda)coreStrategic or Co-development PartnerNippon Soda is listed as a business partner. Japanese chemical and pharmaceutical company with potential for collaboration in human or animal health antibody therapeutics.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

MabGenesis competitors and assessment

Company assessment

Broad incumbents

  • GenScript ProBio: Biologics CDMO offering antibody discovery, engineering, and manufacturing services. Comparable as a B2B antibody discovery service provider with broader manufacturing scope.
  • WuXi Biologics: Global biologics CRO/CDMO offering antibody discovery, development, and manufacturing services to pharma. Comparable as a large-scale antibody discovery service provider, though broader scope and scale than MabGenesis.
  • Zoetis: Largest global animal health company and a potential customer/partner for companion animal antibody therapeutics. Comparable as a major channel for veterinary biologics — relevant to MabGenesis's animal health partnerships.

Direct peers

  • AbCellera Biologics: Vancouver-based antibody discovery platform company using single-cell screening and proprietary libraries to discover monoclonal antibody candidates for pharma partners. Directly comparable B2B business model centered on antibody out-licensing and platform partnerships.
  • Adimab: Leading yeast-display-based antibody discovery platform providing partnered antibody discovery, optimization, and licensing to pharma. Closely mirrors MabGenesis's display library + pharma partnership model.
  • AnaptysBio: Antibody discovery and development company using proprietary somatic hypermutation platforms to generate therapeutic mAbs for immuno-oncology and inflammation. Comparable as a discovery-stage antibody platform monetizing via licensing and partnerships.

Emerging players

  • Twist Bioscience: Synthetic DNA and antibody library provider with phage-display libraries sold to pharma and biotech. Comparable via display-library technology offerings, though broader in synthetic biology scope.
  • Harbour BioMed: Biotech specializing in heavy-chain-only antibody (HCAb) and bispecific discovery using transgenic mouse and phage display platforms. Comparable via display-library technology and antibody platform licensing to pharma.
  • Crescendo Biologics: Developer of T cell engagers based on a humanized VHH (camelid single-domain antibody) platform. Comparable to MabGenesis's cVHH MOURA Library work on VHH-derived therapeutics.

Regional players

  • IDEXX Laboratories: Animal diagnostics and veterinary products company with deep companion animal channel reach. Relevant as a potential downstream partner or comparator in the companion animal therapeutics/diagnostics ecosystem.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

MabGenesis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MabGenesis leadership team

Management profile

Number of profiles

Profiles2 records

MabGenesis funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MabGenesis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MabGenesis

What does MabGenesis do?

MabGenesis commercializes a proprietary antibody discovery platform — the MOURA Library (human, canine, feline, camelid VHH, and cancer cell-specific phage display libraries) together with the IMPACT screening method — to deliver therapeutic monoclonal antibody candidates for human and companion animal applications. The company sells its discovery services and platforms through research collaboration agreements, pipeline co-development, and technology licensing to pharmaceutical and animal health partners.

Is MabGenesis a public or private company?

MabGenesis is a private company. It is classified as venture growth investor backed and is currently operating.

When was MabGenesis founded?

MabGenesis was founded in 2019. It employs 1 to 10 people.

Where is MabGenesis based?

MabGenesis is headquartered in Yokohama, Japan, in the Asia region.

How does MabGenesis make money?

Two revenue lines are on record. Research Collaboration is the primary driver. The others are technology Licensing.

Who are MabGenesis's main competitors?

Broad incumbents on record are GenScript ProBio, WuXi Biologics and Zoetis. Direct peers are AbCellera Biologics, Adimab and AnaptysBio. Emerging players are Twist Bioscience, Harbour BioMed and Crescendo Biologics. IDEXX Laboratories is listed as a regional player.

Does MabGenesis have an API?

No public API is recorded for MabGenesis.

What industry is MabGenesis in?

MabGenesis's product category is Therapeutic Antibody Discovery & Biopharmaceutical R&D Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals